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Long-term reduction of plasma homocysteine levels by super- been related to increased rates of known risk factors,
flux dialyzers in hemodialysis patients. such as hypertension, hyperlipidemia, diabetes mellitus,
Background. Hyperhomocysteinemia is an independent risk and smoking. However, recent studies suggest that thesefactor for cardiovascular disease in chronic hemodialysis (CHD)
risk factors do not fully explain the high prevalence ofpatients. Treatment with folic acid normalizes total homocys-
CVD in this patient group [1]. Recently, hyperhomocys-teine (tHcy) in only a minority of the patients. The present
investigation has been conducted to study the influence of vari- teinemia has been established as an independent risk
ous dialyzers with different flux characteristics on the reduction factor for CVD, not only in the general population [2–5],
of tHcy in the long term. but also in CHD patients [6, 7]. As hyperhomocysteine-Methods. Total Hcy, folate, vitamin B6, vitamin B12, and
mia occurs in approximately 85 to 100% of the dialysisalbumin levels were assessed prospectively in 10 patients under-
population, it has been suggested that apart from thegoing HD with high-flux polysulfon (PS; F 60) and 20 patients
with super-flux dialyzers (N 5 10 PS, F 500S; N 5 10 CTA, previously mentioned classic risk factors, elevated plasma
Tricea 150G). Blood samples were collected before hemodialy- homocysteine levels contribute substantially to the high
sis both at the beginning of the study and after 12 weeks.
incidence of CVD in these patients [14].Results. At baseline, all the groups showed similar tHcy
Homocysteine is a sulfhydryl amino acid, resulting fromlevels. During high-flux dialysis, tHcy remained stable. In con-
trast, during dialysis with both super-flux modalities, tHcy de- demethylation of the essential amino acid methionine.
creased significantly (F 500S week 1, 29.6 6 9.9 mmol/L, and Homocysteine can be remethylated to methionine or trans-
week 12, 21.5 6 8.5 mmol/L, P 5 0.007; Tricea 150G week 1, sulfurated to cysteine. There are two different remethyla-
24.4 6 8.7 mmol/L, and week 12, 15.3 6 3.7 mmol/L, P 5 0.008).
tion pathways. The first reaction requires vitamin B12 as aThe difference between high-flux and super-flux dialyzers was
cofactor and 5-methyltetrahydrofolate (5-MTHF), a folichighly significant (mean: high-flux increase 15.6%, super-flux
decrease 33.3%, P 5 0.001). Multivariate analysis showed a acid metabolite, as methyldonor. The second reaction
significant effect of super-flux dialysis on tHcy (P 5 0.001), requires betaine as methyldonor. The transsulfuration
independently of the previously mentioned variables. pathway consists of two irreversible, vitamin B6-depen-Conclusions. Our findings clearly show that both types of
dent reactions (Fig. 1).super-flux dialyzers reduced tHcy significantly. As the molecu-
The pathophysiological mechanism of hyperhomocys-lar weight of free homocysteine is less than 268 D, the most
teinemia in CHD patients is unclear. A lack of elimina-likely explanation seems to be the removal of uremic toxins
with inhibitory activities against enzymes involved in the extra- tion as a result of a decreased renal clearance seems
renal homocysteine metabolism. unlikely, as the urinary excretion of homocysteine is
negligible in healthy subjects [8]. Accumulation caused
by a decreased intrarenal metabolism of homocysteine
Cardiovascular disease (CVD) is a major cause of mor- in end-stage renal disease (ESRD) patients seems im-
bidity and mortality in chronic hemodialysis (CHD) pa- plausible as well. In contrast to experiments in rats [9],
tients. The high prevalence of atherosclerotic disease has recent data in healthy volunteers showed no arteriove-
nous homocysteine differences in the kidneys, indicating
that renal extraction does not occur in fasting humansKey words: high-flux dialyzers, cellulosic triacetate, dialysis, hyper-
homocysteinemia, cardiovascular disease, uremic toxins. [10]. Therefore, the inhibition by uremic toxins of en-
zymes involved in the extrarenal homocysteine removalReceived for publication February 24, 2000
has been suggested as an alternative explanation for theand in revised form July 19, 2000
Accepted for publication July 21, 2000 elevated homocysteine levels in ESRD patients [10, 11].
Indeed, according to a recent study, most of the abnor-Ó 2001 by the International Society of Nephrology
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Fig. 1. Homocysteine metabolism. Abbrevi-
ations are: AdoMet, S-adenosylmethionine;
AdoHcy, S-adenosylhomocysteine; THF, tetra-
hydrofolate; 5-MTHF, 5-methyltetrahydrofo-
late; 5,10-MeTHF, 5,10-methylene-tetrahydrofo-
late; MTHFR, 5,10-methylene-tetrahydrofolate
reductase; MHMT, methyltetrahydrofolate-
homocysteine methyltransferase; BHMT, be-
taine-homocysteine methyltransferase; CBS,
cystathionine b-synthase.
Table 1. Patient characteristicsmalities of homocysteine metabolism in renal failure can
be explained by a refractoriness of the folate and/or High-flux Super-flux
N 5 10 N 5 20vitamin B12-dependent remethylation pathway as men-
Age yearstioned previously in this article (Fig. 1) [12]. Several
Median range 65 (25–86) 70 (21–82)studies in CHD patients have shown that treatment with
Gender
folic acid, either alone or in combination with other Men 7 11
Women 3 9B vitamins, reduced total homocysteine (tHcy) levels
Time on hemodialysis monthsmarkedly [13, 14]. However, with the exception of one
Median range 39 (8–200) 30 (10–301)
recent report [15], vitamin supplementation failed to nor- Dialysis dose (Kt/Vurea) 0.87 1.13
Residual creatinine clearance mL/min 0.44 0.87malize plasma tHcy entirely in the vast majority of these
patients [16, 17]. The effect of hemodialysis itself on
plasma tHcy concentration has been investigated in only
a small number of uncontrolled studies [18–21]. Interest-
ingly, the reduction in tHcy was not markedly different high-flux devices. Use of such dialyzers may thus lead
to a more sustained reduction or even normalization ofbetween high- and low-flux devices [20]. If one accepts
the view that hemodialysis can lower plasma tHcy only plasma tHcy in the long term. In this report, we describe
the first prospective randomized and controlled studyby elimination through the filter, the latter observation
would be expected, given the molecular weight of free that examines the effect of three types of dialyzers with
different flux characteristics (high- and super-flux) andhomocysteine in plasma (that is, 268 D or lower). How-
ever, using low-flux dialyzers, Arnadottir et al have membrane materials [polysulfon (PS) and cellulosic tri-
acetate (CTA)] on plasma tHcy levels in CHD patients.shown that the creatinine concentration rose immedi-
ately after HD, whereas the reduction in plasma tHcy
persisted for 8 to 20 hours [11]. Thereafter, a gradual
METHODS
increase was observed, reaching predialysis values after
Patients44 hours. Based on these findings, it was suggested that
the intradialytical decline resulted from the removal of Thirty stable CHD patients (18 men and 12 women)
with a median age of 69 years (range of 25 to 82) partici-unbound homocysteine. The reduction that persisted for
20 hours after HD was attributed to the elimination of pated in the study after giving written informed consent.
All patients had been on maintenance HD for at leasturemic toxins with inhibitory activity against relevant
enzymes, involved in the metabolism of homocysteine. eight months (median 32.5, range 8 to 301). Patient char-
acteristics are shown in Table 1. Causes of renal insuffi-Therefore, it is conceivable that dialyzers with superior
flux and/or adsorptive characteristics are capable of re- ciency were hypertension (N 5 10), diabetic nephropa-
thy (N 5 4), polycystic kidney disease (N 5 3), focalmoving such toxins more effectively than conventional
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Table 2. Membrane characteristics
F 60 F 500S Tricea 150G
Inner lumen lm 200 155 200
Wall thickness lm 40 35 15
Ultrafiltration coefficient mL/mm Hg/h 40 300 (H2O) 29
Surface area m2 1.3 1.2 1.5
Clearance mL/min
b2-microglobulin (molecular weight 11.8 kD) 38 65–80 Not known
Sieving coefficient b2-microglobulin 0.65 0.9 0.8
glomerulosclerosis (N 5 3), chronic pyelonephritis (N 5 Homocysteine. Total homocysteine was measured in
NaFK2-oxalate plasma by means of high-performance1), chronic glomerulonephritis (N 5 3), renal failure of
unknown origin (N 5 4), and others (N 5 2). Exclusion liquid chromatography (HPLC) with fluorescence detec-
tion according to the method of Ubbink, Vermaak, andcriteria were hemodialysis for less than eight months,
Bissbort [22]. The upper limit of the reference range wasvitamin B12 supplementation before entering the study,
,15 mmol/L. The intra-assay coefficient of variation wassevere malnutrition (albumin ,25 g/L), and current use
about 8%.of anticonvulsant drugs. All patients received folic acid,
Folate and vitamin B12. Serum levels were determined5 mg twice a week, 1 mg vitamin B6 daily, whereas neither
by using an automated luminiscence-immuno-assay (LIA,betaine nor vitamin B12 was prescribed to the participants
ACS: 180; Bayer, Mijdrecht, The Netherlands). Refer-of the study. Approval of the local ethical committee
ence ranges were .5 nmol/L and 150 to 670 pmol/L,was obtained.
respectively, and the intra-assay coefficient of variation
Study design ranged from 5 to 10%.
Vitamin B6. Vitamin B6 (pyridoxal 59-phosphate) wasBefore participating in the study, all patients were
established in heparin blood, applying HPLC with post-dialyzed three times a week using a high-flux PS dialyzer.
column derivation (Analytico, Center for Research,After computerized randomization, the patients were
Breda, The Netherlands). The reference range was 40dialyzed either with a high-flux PS, a super-flux PS, or
to 100 nmol/L, and the intra-assay coefficient of variationa super-flux CTA dialyzer for 12 weeks. Blood samples
ranged from 5 to 8%.were collected both at the start of the study and after
Albumin. Serum concentrations were measured using12 weeks. Blood samples were drawn from the afferent
nephelometry (Behring Nephelometer II; Behring, Leus-line before dialysis and analyzed for tHcy, vitamin B6,
den, The Netherlands). The reference interval rangedvitamin B12, folate, and albumin.
from 35 to 52 g/L. The intra-assay coefficient of variation
Dialysis procedure and materials was approximately 5%.
Adequacy of dialysis. Kt/Vurea was measured using anThe dialysis sessions lasted three to five hours, de-
urea monitor (Biostat; Baxter, Utrecht, The Netherlands).pending on the individual prescription of the patient.
This measurement was performed by means of a mem-Only first-use dialyzers were used. Characteristics of the
brane bound urease and an ammonium-ion–selectivethree dialyzers used in this study (PS, F 60 and F 500 S;
electrode, which measures the ammonium generated byFresenius, Bad Homburg, Germany; CTA, Tricea 150 G;
the reaction: urea ! (urease)ammonia (upper and lowerBaxter, Osaka, Japan) are depicted in Table 2. According
detection levels of urea, 1.0 to 28.5 mmol/L and precisionto the individual needs of the patients, blood flow and
1.8%). Correction for the two-compartment model wasultrafiltration (UF) rates were kept constant between 200
performed by the formula of Daugirdas: eKt/V 5 Kt/Vand 250 mL/min and 300 to 1000 mL/hours, respectively.
[1 2 (0.06/T)] 1 0.03 [23].Isolated UF was not performed. Bicarbonate dialysate
was used with a dialysate flow of 500 mL/min. Anticoagu-
Statistical analysislation was achieved by dalteparin with an initial dose of
Data are expressed as mean 6 SD or median and2500 to 6000 IU, followed by an extra dose of 500 to 1000
range when appropriate. Analysis was performed withIU during the dialysis treatment if necessary. Individual
the Statistical Package for Social Sciences/PC1 softwareconditions (blood flow, UF, dalteparin dose) were kept
system using paired and unpaired t tests to study thestable throughout the study period.
differences between groups. Correlation coefficients were
Analytical methods calculated with the Pearson test. Multivariate analysis
was performed to test the relationship between tHcy andAfter collection, the blood samples were immediately
centrifuged and stored at 2208C until required for different dialysis modalities. Differences were consid-
ered statistically significant at P , 0.05.testing.
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Fig. 3. Clearance of tHcy in percentage of high-flux (h; F 60) and
super-flux (j; F 500S and Tricea 150G) dialysis. A significant difference
was observed between these modalities during 12 weeks of treatment
(*P 5 0.001). No marked differences were observed between both
super-flux dialyzers.Fig. 2. Plasma concentrations of total homocysteine (tHcy) in mmol/L
(mean 6 SD) before hemodialysis at the start of the study and after
12 weeks with a high-flux dialyzer (d; PS, F 60) and both super-flux
devices (r; PS, F 500S; CTA, Tricea 150G). During dialysis with both
super-flux devices, tHcy levels decreased significantly (*P 5 0.001).
vs. (F 500S 1 Tricea 150G): F 60 1 15.6%, [F 500S 1
Tricea 150G] 233.3%, P 5 0.001]. The combined data
are shown in Figures 2 and 3. Both before and after three
RESULTS months of high-flux dialysis, normal values of tHcy (,15
mmol/L) were observed in only 20% of the patients,Vitamin B6, vitamin B12, folate, and albumin
whereas super-flux dialysis showed normalization in 50%At baseline, none of the patients had a deficiency of
of the patients after three months.vitamin B12. Two patients had subnormal vitamin B6 lev-
els, and one patient had a subnormal folate level, proba- Relationship between concentrations of vitamin
bly because of noncompliance. The mean serum folate
cofactors, albumin, patient-related characteristics,
level was 126.6 6 103.6 nmol/L. Serum vitamin B12 was and homocysteine354.4 6 163.7 pmol/L. Serum vitamin B6 was 185.6 6
Both at the beginning of the study and after 12 weeks,148.4 nmol/L, and serum albumin was 36.9 6 3.9 g/L.
no significant correlations were found between vitaminNo significant differences were observed between the
cofactors, albumin, age, sex, time on dialysis, residualthree study groups.
creatinine clearance, Kt/V, or tHcy.
Homocysteine Multivariate analysis, comparing high-flux and super-
flux dialysis, showed a significant effect of super-fluxAt baseline, all the groups showed comparable tHcy
dialysis on tHcy levels [F 5 13.58; degree of freedomlevels (F60, 23.1 6 9.7 mmol/L; F500S, 29.6 6 9.9 mmol/L;
(1, 27), P 5 0.001]. No interaction was found with theand Tricea 150G, 24.4 6 8.7 mmol/L, P 5 0.28).
previously mentioned factors, which are known to influ-High-flux. During high-flux dialysis, tHcy levels re-
ence tHcy levels.mained stable (week 1, 23.1 6 9.7 mmol/L; week 12, 26.7 6
14.2 mmol/L, P 5 0.25). The percentage of patients with
normal tHcy level did not change.
DISCUSSIONSuper-flux. In contrast, during dialysis with both super-
The present study was designed to evaluate three dif-flux dialyzers, tHcy levels decreased significantly (F 500S,
ferent dialyzers, including two types of super-flux de-29.6 6 9.9 mmol/L in week 1 vs. 21.5 6 8.5 mmol/L in
vices, with respect to their long-term effects on tHcyweek 12, P 5 0.007; Tricea 150G, 24.4 6 8.7 mmol/L in
levels in CHD patients. Interestingly, both super-fluxweek 1 vs. 15.3 6 3.7 mmol/L in week 12, P 5 0.008).
dialyzers (F 500S and Tricea 150G) reduced plasma tHcyMarked differences were not found between the two
more effectively than the high-flux dialyzer (F 60) usedsuper-flux dialyzers (F 500S, 28.1 6 7.3 mmol/L; Tricea
in this study. After 12 weeks of super-flux dialysis, tHcy150G, 29.1 6 8.5, P 5 0.78).
was within the reference range in 50% of the patients,High-flux versus super-flux. The change in tHcy levels
in contrast to 20% after high-flux HD. This finding mayduring the study period was significantly different be-
have important consequences in clinical practice as hy-tween the high-flux device and the two super-flux dialyz-
perhomocysteinemia is common in CHD patients anders, either alone or combined [F 60 vs. F 500S: F 60 1
associated with an adverse cardiovascular outcome15.6%, F 500S 227.4%, P 5 0.006; F 60 vs. Tricea 150G:
F 60 1 15.6%, Tricea 150G 237.3%, P 5 0.005; F 60 [7, 24].
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There is no unifying theory that explains the patho- months of HD with super-flux dialyzers, depends on the
physiological mechanism of hyperhomocysteinemia. removal of such substances is currently under investigation.
Growing evidence indicates that hyperhomocysteinemia It is of note that super-flux CTA and PS membranes
exerts its toxic effects by promoting oxidative stress. showed a comparable decline after 12 weeks of treat-
During auto-oxidation of homocysteine, various reactive ment. Interestingly, as shown by multivariate analysis,
oxygen species are formed [25]. In vitro studies have the use of super-flux dialyzers was the only significant
shown that hyperhomocysteinemia is associated with im- predictor in reducing plasma tHcy. In contrast to other
paired endothelium-dependent relaxation, which is at- investigations [33, 34], our study showed no clear correla-
tributed to a reduced bioavailability of nitric oxide [26, 27]. tions between folate, vitamin B6, vitamin B12, albumin
So far, these data are consistent with the idea that hy- concentration, and tHcy levels, either at the start or after
perhomocysteinemia contributes to the development of 12 weeks. As for serum folate, the lack of correlation
atherosclerosis. Alternatively, however, it has been pos- may be due to supraphysiological values resulting from
tulated that hyperhomocysteinemia results from cell in- abundant supplementation.
jury rather than being the cause of it [28]. Whatever the In conclusion, our findings clearly show that hemodial-
underlying mechanism and pathophysiology of hyperho- ysis with super-flux dialyzers is more effective in reducing
mocysteinemia in ESRD patients, long-term normaliza- plasma tHcy levels than high-flux dialyzers. The decline
tion of plasma tHcy seems desirable for three reasons. was independent of other factors, which are known to
First, low homocysteine levels are clinically associated influence plasma tHcy levels. Whether long-term nor-
with a low cardiovascular risk profile [7]. Second, hyper- malization of tHcy levels results in improvement of endo-
homocysteinemia is associated with cytotoxic effects on thelial dysfunction and a reduction of CVD in CHD
various cell types, such as thrombocytes, leukocytes, and patients deserves further study.
endothelial cells [abstract; Guo et al, Neth J Med 52
(Suppl 1):S58, 1998] [29]. Third, a drop in plasma tHcy ACKNOWLEDGMENTS
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